Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 8Terminated 2Active not recruiting 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Rectal Neoplasms 2Melanoma 2Triple Negative Breast Neoplasms 1Sarcoma, Kaposi 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Neuroma, Acoustic 1Neurofibromatosis 2 1Meningioma 1Lymphoma, Large B-Cell, Diffuse 1Liver Neoplasms 1Glioma 1Ependymoma 1Differentiated Thyroid Cancer 1Carcinoma, Hepatocellular 1Breast Neoplasms 1Biliary Tract Neoplasms 1Acquired Immunodeficiency Syndrome 1AIDS-related Kaposi sarcoma 1

Interventions

pembrolizumab 51Ipilimumab 50Cyclophosphamide 43Nivolumab 41aldesleukin 30Interleukin-2 23Vemurafenib 20fludarabine 19Temozolomide 18fludarabine phosphate 15dabrafenib 15trametinib 12spartalizumab 10Radiotherapy 10Radiosurgery 10Dacarbazine 10CTLA-4 Antigen 10cobimetinib 9binimetinib 9poly ICLC 7encorafenib 7Paclitaxel 7atezolizumab 6Introns 6Biopsy 6montanide ISA 51 5Carboplatin 5epacadostat 4MART-1 Antigen 4Interferon alpha-2 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Melanoma × AZD 6244 × Clear all
NCT01519427 2014-06-18

Selumetinib and Akt Inhibitor MK2206 in Treating Patients With Stage III or Stage IV Melanoma Who Failed Prior Therapy With Vemurafenib or Dabrafenib

National Cancer Institute (NCI)

Phase 2 Terminated
2 enrolled 9 charts
Dermatologic

Melanoma

NCT01166126 2014-05-15

Temsirolimus/AZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IV

National Cancer Institute (NCI)

Phase 2 Terminated
4 enrolled 7 charts
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡